Medifast, Inc (MED) Fair Value & Analysis
Consumer Cyclical · US · Market cap $123M
Medifast, Inc
MED · US
Fair value as of: Jun 24, 2026
From 12 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from $10.10 to $7.98 (−21.0%) since Jun 23, 2026. Share price −14.6% over the past month.
Price vs Fair Value (12 months)
12‑month range $9.46 – $15.11 · fair‑value band $7.54 – $8.42 · the $10.62 price screens above the $7.98 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Medifast, Inc (MED) currently trades at $10.62, while our model-based Fair Value estimate is $7.98 — implying the stock looks roughly 24.9% overvalued today. We read business quality at 95/100 (high quality), in the Consumer Cyclical sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Medifast, Inc generated revenue of $346M at a net margin of -5.8%. Revenue declined 34.3% year over year. It earns a return on equity of -9.8%. The balance sheet holds a net cash position of $72.5M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Medifast, Inc., through its subsidiaries, operates as a health and wellness company that provides habit-based and coach-guided lifestyle solutions to address weight loss in the United States. The company offers weight loss, weight management, and healthy living products comprising bars, cereals, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, soups, essential amino acid blends, whey protein, hot beverages, brownies, and mini meals under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE categories, as well as daily nutrient packs, including multivitamins, minerals, and omega-3 fatty acid supplements. It also provides lifestyle plans consisting of 5 & 1 Plan and 5 & 1 ACTIVE Plan, which provides a targeted reset of the body's metabolism by activating strong and targeted fat burn; Optimal Weight 4 & 2 & 1 Plan and Optimal Weight 4 & 2 ACTIVE Plan, which is designed for clients who want to continue eating all…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Medifast, Inc reported revenue of $386M in FY2025 versus $1.5B in FY2021, a compound −29.1%/yr. Reported net income was −$18.7M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Personal Services stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Rollins, Inc ROL | $47.10 | $15.62 | -67% |
| Service Corporation SCI | $73.16 | $36.64 | -50% |
| H&R Block, Inc HRB | $34.04 | $78.83 | +132% |
| Frontdoor, Inc FTDR | $71.87 | $73.55 | +2% |
| Bright Horizons Family Solutions Inc BFAM | $61.54 | $74.79 | +22% |
| Fu Shou Yuan International Group FSHUF | $0.3800 | $0.5500 | +45% |
Explore undervalued stocks
More undervalued Consumer Cyclical stocks →
Frequently asked questions
Is Medifast, Inc (MED) undervalued?
What is the fair value of MED?
What is the quality score of MED?
What is the revenue of Medifast, Inc (MED)?
What is the net profit margin of MED?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.